Alpha lipoic acid supplementation improved antioxidant enzyme activities in hemodialysis patients

Area of Science:

• Biochemistry
• Clinical Nutrition
• Nephrology

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in hemodialysis (HD) patients.
• Oxidative stress, linked to reduced activity of antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), is a significant risk factor for CVD in HD patients.
• Alpha lipoic acid (ALA) is a potent antioxidant with potential to modulate these key enzymes.

Purpose of the Study:

• To investigate the impact of ALA supplementation on the activity of primary antioxidant enzymes in patients undergoing hemodialysis.
• To assess whether ALA can mitigate oxidative stress markers in this vulnerable patient population.

Main Methods:

• A double-blinded, randomized clinical trial involving 63 hemodialysis patients.
• Participants were assigned to receive either 600 mg of ALA daily or a placebo for 8 weeks.
• Blood samples were analyzed pre- and post-intervention for antioxidant enzyme activities (SOD, CAT, GPx), albumin, and hemoglobin levels.

Main Results:

• ALA supplementation led to an increase in the mean blood activities of SOD, GPx, and CAT.
• The increase in SOD activity was statistically significant when compared to the placebo group (P = 0.04).
• No significant changes were observed in albumin, hemoglobin, weight, or body mass index (BMI) between the groups.

Conclusions:

• Alpha lipoic acid supplementation may offer benefits to hemodialysis patients by enhancing antioxidant enzyme activity, particularly SOD.
• While promising, further research is required to confirm these findings and establish precise therapeutic outcomes.
• ALA's role in managing oxidative stress in HD patients warrants continued investigation.